84 Kodiak Sciences Inc. Consolidated Balance Sheets (in thousands, except share and per share amounts) December 31, 2022 December 31, 2021 Assets Current assets: Cash and cash equivalents ............................................................................................. $ 190,433 $ 731,510 Marketable securities .................................................................................................... 288,500 — Prepaid expenses and other current assets........................................................................ 7,072 3,301 Total current assets ................................................................................................... 486,005 734,811 Restricted cash ................................................................................................................. 6,324 6,324 Property and equipment, net............................................................................................... 56,384 41,330 Operating lease right-of-use asset....................................................................................... 59,369 66,744 Other assets...................................................................................................................... 58,546 55,011 Total assets .............................................................................................................. $ 666,628 $ 904,220 Liabilities and stockholders’ equity Current liabilities: Accounts payable.......................................................................................................... $ 9,130 $ 12,431 Accrued and other current liabilities ............................................................................... 33,440 48,319 Operating lease liability................................................................................................. 9,926 3,933 Total current liabilities .............................................................................................. 52,496 64,683 Operating lease liability, net of current portion .................................................................... 77,807 76,063 Liability related to sale of future royalties ........................................................................... 99,996 99,943 Other liabilities................................................................................................................. 162 211 Total liabilities ......................................................................................................... 230,461 240,900 Commitments and contingencies (Note 8) Stockholders’ equity: Preferred stock, $0.0001 par value, 10,000,000 shares authorized; 0 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively ................................................................................. — — Common stock, $0.0001 par value, 490,000,000 shares authorized at December 31, 2022 and December 31, 2021; 52,333,850 and 51,826,257 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively ................................................................................. 5 5 Additional paid-in capital .................................................................................................. 1,329,509 1,221,532 Accumulated other comprehensive income (loss)................................................................. (1,307) — Accumulated deficit.......................................................................................................... (892,040) (558,217) Total stockholders’ equity.......................................................................................... 436,167 663,320 Total liabilities and stockholders’ equity ..................................................................... $ 666,628 $ 904,220 The accompanying notes are an integral part of these consolidated financial statements.